Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions [press release]
Activators of PPAR as mentioned previously, including the thiazolidinediones, increase insulin sensitivity but are associated with weight gain through induction of adipogenesis
The underlying cause of deficiency matters
These studies suggest GLP-1 drugs may one day, after robust clinical trials, be used by many more people than they are today, says Professor Marcin Chwistek, Chief of Supportive Oncology and Palliative Care Program at Fox Chase Cancer Center
This is a lower fat, lower calorie diet formulated to help dogs lose weight, or for dogs prone to obesity